《疾病蛋白质组学》演示PPT

1、1 第四讲第四讲 疾病蛋白质组学（一）疾病蛋白质组学（一） disease proteomics 2 一、基本概念和总体研究概况一、基本概念和总体研究概况 3 疾病蛋白质组学疾病蛋白质组学 disease proteomics 运用蛋白质组学研究手段，通过比较正常和病理情况下细运用蛋白质组学研究手段，通过比较正常和病理情况下细 胞、组织或体液中蛋白质在组成成分、表达水平、表达位胞、组织或体液中蛋白质在组成成分、表达水平、表达位 置和修饰状态上的差异，寻找置和修饰状态上的差异，寻找疾病诊断和预后的特异性蛋疾病诊断和预后的特异性蛋 白质白质( (群群) )，包括特异性抗原及相关抗原、受体、酶等，以

2、，包括特异性抗原及相关抗原、受体、酶等，以 及及药物治疗的靶标药物治疗的靶标等。通过深入了解这些疾病特异性蛋白等。通过深入了解这些疾病特异性蛋白 质的结构和功能，揭示疾病过程中细胞内全部蛋白质的活质的结构和功能，揭示疾病过程中细胞内全部蛋白质的活 动规律，为多种疾病发生、发展机制的阐明和早期诊断及动规律，为多种疾病发生、发展机制的阐明和早期诊断及 治疗提供理论根据和解决途径。治疗提供理论根据和解决途径。 4 研究进展研究进展 肿瘤蛋白质组：肿瘤蛋白质组： 研究细胞的增殖、分化、异常转化、肿瘤形成研究细胞的增殖、分化、异常转化、肿瘤形成 白血病、乳腺癌、结肠癌、膀胱癌、前列腺癌、肺癌、肾癌、肝细

3、胞癌白血病、乳腺癌、结肠癌、膀胱癌、前列腺癌、肺癌、肾癌、肝细胞癌 和神经母细胞瘤等和神经母细胞瘤等 联合联合激光捕获微切割技术激光捕获微切割技术(Laser capture mierodisseetion，LCM)，直接从肿瘤，直接从肿瘤 组织中提取纯肿瘤细胞，组织中提取纯肿瘤细胞， 以克服组织内异质性的问题以克服组织内异质性的问题 ，为肿瘤蛋白质组研究，为肿瘤蛋白质组研究 提供了技术上的保障。提供了技术上的保障。 鉴定了一批肿瘤相关蛋白，为肿瘤的早期诊断、药靶的发现、疗效和预后的鉴定了一批肿瘤相关蛋白，为肿瘤的早期诊断、药靶的发现、疗效和预后的 判断提供了重要依据。判断提供了重要依据。 在

4、心脏、肺部在心脏、肺部 、内分泌系统、神经系统疾病、药物成瘾性、内分泌系统、神经系统疾病、药物成瘾性 、环境毒、环境毒 理学理学 、传染病、内耳相关疾病等方面，蛋白质组研究成果也为其提、传染病、内耳相关疾病等方面，蛋白质组研究成果也为其提 供了新的诊疗方向。供了新的诊疗方向。 国内：重点在肝病、恶性肿瘤、心血管、神经系统疾病和新发传染病国内：重点在肝病、恶性肿瘤、心血管、神经系统疾病和新发传染病 等方面等方面 5 存在问题和发展趋势存在问题和发展趋势 利用蛋白质组研究的人类疾病的范围虽然日趋扩大，但利用蛋白质组研究的人类疾病的范围虽然日趋扩大，但 仍停留在初级比较阶段。仍停留在初级比较阶段。

5、进一步鉴定、验证，发展成应用于临床的生物标志物进一步鉴定、验证，发展成应用于临床的生物标志物 开展全方位的蛋白质组相互作用网络的分析开展全方位的蛋白质组相互作用网络的分析 进一步提高蛋白分离和鉴定的通量、灵敏度和规模；进一步提高蛋白分离和鉴定的通量、灵敏度和规模； 提高生物信息学应用范围与准确率，进行信息综合，准提高生物信息学应用范围与准确率，进行信息综合，准 确地分析蛋白质的相互作用，界定相互作用连锁群；确地分析蛋白质的相互作用，界定相互作用连锁群； 6 二、心血管疾病蛋白质组学二、心血管疾病蛋白质组学 Cardiovascular Proteomics the cardiovascular

6、 (CV) system is composed of a number of specialized cell types including cardiac myocytes, fibroblast, neurons, endothelial and smooth muscle cells and newly discovered stem and progenitor cells. To date, the proteome of these cells are not well characterized nor has the interplay between the cell t

7、ypes been established in health or disease. This remains a significant challenge as CV disease is the number one killer world wide. 7 Research Focus The myofilament proteome. Redox modifications in the cardiac proteome. Cardiac biomarkers. Secretory microvesicles Proteomics of the secretome 8 The my

8、ofilament proteome The myofilament （肌丝）（肌丝）proteins are responsible for the contractile nature of the cardiac myocytes. the myofilament subproteome allows the heart to act as a pump. The myofilament proteins are highly regulated by a number of specific post-translational modifications (PTMs) some of

9、 which have been discovered through proteomic studies. PTMs of myofilament proteins can directly impact on the contractility of the heart. 9 A simplified illustration of the cardiac myofilament proteins. The thick filament proteins consist of myosin heavy chain (MHC), myosin-binding protein C (MyBP-

10、 C), and two myosin light chains (MLC1 and MLC2). The thin filament proteins consist of actin, tropomyosin (Tm), and the three components of troponin; troponin I (TnI), troponin C (TnC) and troponin T (TnT). Phosphorylation sites on the myofilament proteins are indicated with a small diamond. The la

11、rge scaffolding protein, titin, which spans the sarcomere, is not included in this illustration. 肌球蛋白重链肌球蛋白重链(MHC): myosin heavy chain 肌球蛋白轻链肌球蛋白轻链-1,2(MLC1,2): myosin light chain-1,2 肌动蛋白：肌动蛋白：Actin 肌球蛋白结合蛋白肌球蛋白结合蛋白C(MyBP-c): myosin binding protein C） 肌钙蛋白肌钙蛋白(TnT, TnI, TnC): troponin T, I ，C -原肌球蛋

12、白原肌球蛋白(Tm)： -tropomyosin 肌联蛋白肌联蛋白: titin 10 Structure of a region of the overlap region of a cardiac sarcomere in diastole on the left and during systole on the right with indications of major and functionally significant protein phosphorylation sites. 11 Post-translational modifications of myofilam

13、ent proteins 12 13 Sample preparation There are two commonly used myofilament protein- enrichment strategies. Both methods are compatible with 1-DE and 2-DE analysis： TFA (trifluoroacetic acid, 三氟醋酸三氟醋酸) extraction ：cells are lysed with low ionic buffer, and myofilament proteins are extracted from t

14、he resulting pellet with 1% TFA v/v. applied to extract myofilament proteins from minute amounts (20,50 mg) of biopsy samples.（ref: Proteomics 2002, 2, 978987.) Myofibril isolation：intact myofibrils can be isolated form detergent-skinned (detergent extraction) heart muscle and stored in 50% glycerol

15、 at -20 C. (ref: FASEB J. 2005, 19, 11371139.) 14 Detection Methods for Protein modification phosphorylation changes: 1-D-IEF (phosphorylation significantly decreases protein pI values) Western blots with phosphorylation-site-specific antibodies MS analysis: MALDI-TOF coupled with phosphatase treatm

16、ent or Post source decay (PSD) immobilized metal affinity column (IMAC) enrichment and LC separation followed by MS/MS analysis 15 Immobilized metal affinity column (IMAC) Schematic of affinity binding of phosphopeptides to immobilized metal ion affinity columns. 16 Detection Methods for Protein mod

17、ification Protein degradation: 1-D-gel separation followed by Western blot 2-DE, 2-D DIGE direct sequencing from the N terminus or MS (exact site of degradation) oxidation and nitrosylation: gel electrophoresis(change apparent MWand pI values ) nano-ESI LC/MS/MS (identify nitrotyrosine residues) “to

18、p-down” MS (傅里叶转换离子回旋共振质谱）傅里叶转换离子回旋共振质谱） 17 文献阅读文献阅读 Proteomics Clin. Appl. (2008) Chao Yuan, R. John Solaro. Myofilament proteins: From cardiac disorders to proteomic changes (p 788-799) Wenhai Jin, Anna T. Brown, Anne M. Murphy. Cardiac myofilaments: from proteome to pathophysiology (p 800-810) 18

19、 2. Redox modifications in the cardiac proteome Myocardial ischemia results in oxidative stress, which involves the mitochondria and many/all aspects of myocyte function. Due to the susceptibility of cardiac protein to oxidative damage, proteomics can help to discover, quantify, and characterize the

20、 redox signaling and oxidative PTMs. Nitric oxide is a key mediator of CV cellular response in acute and chronic disease settings. New approaches in the proteomics can help identify and define important pathway of nitric oxide-induced PTMs. 19 Outline of potential consequences of oxidative stress in

21、 cell system Oxidants can react with proteins to cause one of two broad consequences. They can oxidise cellular components such as proteins, rendering them dysfunctional, which negatively affects cell function and promotes disease. In this scenario, antioxidants can prevent the cellular proteins fro

22、m being oxidised and so provide protection. In contrast, oxidants can induce regulatory post-translational oxidative protein modifications, which are important for stress adaptation. Thus, antioxidants can interfere with homeostatic control and might explain why antioxidant therapies can be detrimen

23、tal in some cases. 20 Mechanisms of ROS generation. Sequential reduction of molecular oxygen to generate superoxide, hydrogen peroxide and then hydroxyl radical. List of amino acids particularly susceptible to modification. 21 Diagram showing the production of NO and RNS, with their effects on biolo

24、gical targets. At high concentrations, NO reacts mainly with oxygen superoxide forming peroxynitrite (ONOO) and peroxynitrous acid (ONOOH). In this way, NO is intimately linked with ROS. Moreover, the reaction of NO with O2 leads to the formation of the highly poisonous nitrogen dioxide (NO2), dinit

25、rogen tetroxide (N2O4), or both. At low concentrations, the direct effects of NO predominate (dashed arrow) and haems and redox metals at ironsulphur centres in proteins are the main targets. Ni-NOR, nitrite:nitric oxide reductase; Ni, nitrite reductase; NOS, nitric oxide synthase; NR, nitrate reduc

26、tase; RSNOs, S-nitrosothiols. 22 Structure of common redox modifications of amino acid side chains. ROS and RNS can chemically modify amino acids, particularly the side chains of those outlined here. Clearly, cysteine thiols are subject to a diverse range of alterations. 亚磺酸亚磺酸磺酸磺酸次磺酸次磺酸 亚砜亚砜 亚硝基硫醇亚

27、硝基硫醇 羰基化羰基化 硝基化酪氨酸硝基化酪氨酸 23 Commonly observed oxidative modifications of protein amino acids (A) cysteine; (B) methionine; (C) tyrosine; (D) tryptophan. All the amino acids are schematically represented as part of a polypeptide chain. However, the names shown are those of free amino acids for conven

28、ience. 24 List of the most utilized methods in redox proteomics From: Journal of Experimental Botany, Vol. 59, No. 14, pp. 37813801, 2008 25 Biotin switch method A hypothetical protein is indicated with cysteines in either the free thiol, disulphide, or nitrosothiol conformations. In the first step,

29、 free thiols are blocked using MMTS. Next, nitrosylated cysteine residues are selectively reduced with ascorbate and the newly generated free thiols are finally S- biotinylated with biotin- HPDP. The biotinylated proteins can be detected directly by Western blotting with antibodies specific for biot

30、in or using avidin or streptavidin. Antibodies can be radiolabelled, fluorescently or enzymatically labelled, as is known in the art. Additionally, tagged proteins can also be isolated from affinity columns or beads. PSH, protein sulphhydryl groups; PSNO, Snitrosated proteins. 26 Isotope Coded Affin

31、ity Tagging (ICAT) (a). The reagent consists of three moieties: an affinity tag biotin, a linker that can incorporates stable isotopes, and a maleimide (顺丁烯二酰亚胺顺丁烯二酰亚胺) group which reacts specifically with the thiol group of cysteine. Two labelled forms of the reagent are used, the heavy containing

32、eight deuteriums (氘氘)and the light with none. (b) Proteins from two different cell states are labelled with the light or heavy ICAT reagents. The samples are then combined and digested. The ICAT-labelled peptides are isolated by affinity chromatography using an avidin column and then analysed HPLC-M

33、S (/MS) directly or by MALDI of the collected HPLC fractions. The ratio of the peaks areas for specific ICAT-labelled pairs defines the relative abundance of its parent proteins between the two cell states quantification of protein cysteine oxidation 27 List of cardiac proteins demonstrated to under

34、go oxidative modification Ref: Proteomics Clin. Appl. 2008, 2, 823836 28 3. Cardiac biomarkers Diagnosis of MI relies on the detection in serum of a cardiac specific isoform of the myofilament protein, troponin I which is released into the blood when the cardiac myocyte dies due severe ischemia Earl

35、ier detection of MI or diagnosis of myocardial ischemia prior to cell death will help to allow even earlier intervention to save “potentially viable” heart muscle. proteomic discovery pipeline for analysis of human plasma samples for patients with induced and control MI helped to set the stage for e

36、arlier detection of patents at high risk. 29 Current gold standard markers of CV distress (i) electrophysiological and functional changes as monitored by electrocardiography and echocardiography respectively (ii) elevated serum levels of cardiac specific proteins ： myofilament proteins and cardiac t

37、roponin-I and -T （myocardial infarction） brain natriuretic peptide and inflammation-related proteins, including C-reactive protein (CRP), （heart failure）. cardiac enzymes lactate dehydrogenase and creatine kinase (CK) 30 Several approaches currently used to quantitatively profile global proteomic ex

38、pression patterns fluorescence 2-D DIGE coupled to MS analysis Protein arrays in vitro and in vivo stable isotope label LC-MS techniques Significant cost of using labeled reagents in large-scale studies. the apparent bias of these techniques towards labeling the relatively most abundant species in a

39、 complex mixture, More recently, “label-free” differential (d)MS ( (无标记的质无标记的质 谱定量方法谱定量方法) ) 31 32 Workflow for label-free dMS analysis of plasma samples. (A) Workflow chart. The six stages of the process are represented within this figure including sample preparation, addition of internal standards

40、 and MS analysis. Each stage plays an important role in leading to a successful of determination of meaningful differentials. 33 4. Secretory microvesicles Vascular secretory protein and membrane vesicles can affect homeostasis and communication within entire CV system in response to injury. Schemat

41、ic figure of the use of proteomics for the characterization of the non-cellular protein fractions relevant in atherosclerosis. The figure represents an atherosclerotic plaque and its cellular components. The cells involved in atheroma formation release soluble proteins and membrane bodies that modif

42、y the vascular microenvironment. Proteomics can be applied to the characterization of these non- cellular components of the atherosclerotic microenvironment. 34 The limitations of plasma proteomics plasma and serum are routinely used for biomarker discovery in proteomics. the high-abundance proteins

43、, notably albumin and immunoglobulins, which together with haptoglobulin, antitrypsin and transferrin, typically constitute more than 90% of the total protein mass in human plasma. prospective biomarkers: pgng/ml; albumin: 3550 mg/ml the limited ability of proteomics to detect low-abundance plasma p

44、roteins 35 Proteomics of extracellular secretory vesicles (3) Matrix vesicles are extracellular membrane particles observed in the initial stages of arterial calcification and contain high levels of calcium-binding acidic phospholipids. (4) Apoptotic bodies are large particles released from cells at

45、 the later stages of programmed cell death and characterized by large diameter, nuclear content, and surface ligands for phagocytic cell receptors. (5) Heterogeneous population or secretory microvesicles. (1) Microparticles are released from the plasma membrane of stimulated or apoptotic cells. Thei

46、r protein composition may vary in response to different stimuli (high shear stress, apoptosis, etc.). (2) Exosomes are the smallest of the secretory membrane particles and are secreted as a consequence of the fusion of the plasma membrane with the multivesicular bodies (MVB). MVB are late components

47、 of the endocytic pathway. 36 The critical patho-physiological role of microparticles In the vascular context, microparticles are released by endothelial cells, smooth muscle cells, lymphocytes, monocytes, erythrocytes and platelets. Plasma levels of microparticles are markedly elevated in patients

48、with vein thrombosis, acute coronary disease, ischemic stroke, diabetes, myocardial infarction, and hypertension. Microparticles show pro-coagulant activity, pro-inflammatory, and pro-atherosclerotic activities. modulating the endothelial secretion of prostacyclin and nitric oxide; promote monocyte-

49、endothelium interaction by direct transfer of arachidonic acid to the plasma membrane; physically mediate leukocyte-leukocyte and leukocyte-endothelium interactions via direct binding of cell surface receptors 37 Proteomics of microparticles Proteomic analysis of protein expression in human plasma m

50、icroparticles. Microparticles derived from the peripheral blood by centrifugation were lysed and labelled with Cydyes (green and red colour in A and B, respectively). Using DIGE, microparticle and microparticle-depleted plasma proteins were co-separated in large format 2-D gels. Images were acquired

51、 on a fluorescence scanner and proteins identified by LC-MS/MS. Actin and haemoglobin are enriched in microparticles, compared to microparticle-depleted plasma. 38 characterisation of microparticles released by a particular cell type in vitro by proteomics Besides the investigation of the mixture of

52、 microparticles contained in human plasma, proteomics can be applied to the characterisation of microparticles released by a particular cell type in vitro. platelet microparticles (J. Proteome Res. 2005; 4: 15161521) surface proteins typical of platelets, such as integrin aIIb, integrin b3 and P-sel

53、ectin, and chemokines, such as CXCL4, CXCL7 and CCL5, 380 proteins not previously identified in platelets Endothelial cells in response to stimulation with (TNFa). (Proteomics 2005; 5:44434455) cytoskeleton and cytoskeleton-binding proteins (tubulin, actin, cofilin, vimentin, etc.) membrane-associat

54、ed proteins that control transport and signalling (caveolin, annexins, dynein, etc.) foldingchaperones (calnexin, calreticulin, etc.) Adhesion molecules, such as ICAM-1 and integrins b1, a5 and a2 39 The role of Exosomes modulate immune response regulate haemostatic balance support thrombin generati

55、on and induce expression and secretion of plasminogen activator inhibitor-1 by endothelial cells attenuating fibrinolysis and promoting pro-thrombotic conditions ability to be absorbed to the cell surface and mediate cell- cell interactions in the cardiovascular system 40 Proteomics of exosomes dend

56、ritic cell-derived exosomes (J. Immunol. 2001, 166, 73097318.) endocytic proteins were abundant components of the proteome of exosomes. 21 new exosomal proteins were identified, including cytoskeleton-related proteins, such as cofilin, profilin I or elongation factor 1a, and intracellular membrane transport proteins, such as annexins, rab7, 11, rap 1B, and syntenin. a series of apoptosis-related proteins, including thioredoxin peroxidase II, Alix, 14-3-3, and galectin-3. mast-cell derived exosomes (Arterioscler. Thromb.Vasc. Biol. 200